Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.

Oba J, Esmaeli B, Ellerhorst JA, Lyons GR, Milton DR, Wang WL, Macedo MP, Lazar AJ, Grimm EA, Chattopadhyay C.

Melanoma Res. 2017 Apr;27(2):126-133. doi: 10.1097/CMR.0000000000000329.

PMID:
28118269
2.

Elevated Serum Leptin Levels are Associated With an Increased Risk of Sentinel Lymph Node Metastasis in Cutaneous Melanoma.

Oba J, Wei W, Gershenwald JE, Johnson MM, Wyatt CM, Ellerhorst JA, Grimm EA.

Medicine (Baltimore). 2016 Mar;95(11):e3073. doi: 10.1097/MD.0000000000003073.

3.

Expression of leptin and iNOS in oral melanomas in dogs.

Greene VR, Wilson H, Pfent C, Roethele J, Carwile J, Qin Y, Grimm E, Ellerhorst JA.

J Vet Intern Med. 2013 Sep-Oct;27(5):1278-82. doi: 10.1111/jvim.12169. Epub 2013 Aug 26.

4.

Association of activated c-Met with NRAS-mutated human melanomas.

Chattopadhyay C, Ellerhorst JA, Ekmekcioglu S, Greene VR, Davies MA, Grimm EA.

Int J Cancer. 2012 Jul 15;131(2):E56-65. doi: 10.1002/ijc.26487. Epub 2012 Jan 11.

5.

Clinical correlates of NRAS and BRAF mutations in primary human melanoma.

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA.

Clin Cancer Res. 2011 Jan 15;17(2):229-35. doi: 10.1158/1078-0432.CCR-10-2276. Epub 2010 Oct 25. Erratum in: Clin Cancer Res. 2011 Mar 15;17(6):1641.

6.

Promotion of melanoma growth by the metabolic hormone leptin.

Ellerhorst JA, Diwan AH, Dang SM, Uffort DG, Johnson MK, Cooke CP, Grimm EA.

Oncol Rep. 2010 Apr;23(4):901-7.

7.

Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Eton O, Ross MI, East MJ, Mansfield PF, Papadopoulos N, Ellerhorst JA, Bedikian AY, Lee JE.

J Transl Med. 2010 Jan 29;8:9. doi: 10.1186/1479-5876-8-9.

8.

Genetic deficiency of complement isoforms C4A or C4B predicts improved survival of metastatic renal cell carcinoma.

Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA.

J Urol. 2009 Mar;181(3):1028-34; discussion 1034. doi: 10.1016/j.juro.2008.11.013. Epub 2009 Jan 16.

9.

Frequencies of NRAS and BRAF mutations increase from the radial to the vertical growth phase in cutaneous melanoma.

Greene VR, Johnson MM, Grimm EA, Ellerhorst JA.

J Invest Dermatol. 2009 Jun;129(6):1483-8. doi: 10.1038/jid.2008.374.

10.

Lack of maturation with anti-leptin receptor antibody in melanoma but not in nevi.

Diwan AH, Dang SM, Prieto VG, Ellerhorst JA.

Mod Pathol. 2009 Jan;22(1):103-6. doi: 10.1038/modpathol.2008.166. Epub 2008 Oct 3.

11.

NF-kappaB mediates mitogen-activated protein kinase pathway-dependent iNOS expression in human melanoma.

Uffort DG, Grimm EA, Ellerhorst JA.

J Invest Dermatol. 2009 Jan;129(1):148-54. doi: 10.1038/jid.2008.205. Epub 2008 Jul 31.

12.

Changes in pERK1/2 and pAKT expression in melanoma lesions after imatinib treatment.

Hwang CS, Prieto VG, Diwan AH, Lizee G, Ellerhorst JA, Ekmekcioglu S, Liu P, Eton O, Kinney SA, Grimm EA, Hwu P, Kim KB.

Melanoma Res. 2008 Aug;18(4):241-5. doi: 10.1097/CMR.0b013e3283046146.

13.

Human melanoma cells express functional receptors for thyroid-stimulating hormone.

Ellerhorst JA, Sendi-Naderi A, Johnson MK, Cooke CP, Dang SM, Diwan AH.

Endocr Relat Cancer. 2006 Dec;13(4):1269-77.

14.

Tumor iNOS predicts poor survival for stage III melanoma patients.

Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA.

Int J Cancer. 2006 Aug 15;119(4):861-6.

15.

Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma.

Ellerhorst JA, Ekmekcioglu S, Johnson MK, Cooke CP, Johnson MM, Grimm EA.

Oncogene. 2006 Jun 29;25(28):3956-62. Epub 2006 Feb 13.

PMID:
16474847
16.

Expression of thyrotropin-releasing hormone by human melanoma and nevi.

Ellerhorst JA, Naderi AA, Johnson MK, Pelletier P, Prieto VG, Diwan AH, Johnson MM, Gunn DC, Yekell S, Grimm EA.

Clin Cancer Res. 2004 Aug 15;10(16):5531-6.

17.

HLA class II haplotypes predict favorable outcomes for patients with metastatic RCC.

Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA.

Urologe A. 2004 Sep;43 Suppl 3:S137. No abstract available.

PMID:
15148575
18.

High prevalence of hypothyroidism among patients with cutaneous melanoma.

Ellerhorst JA, Cooksley CD, Broemeling L, Johnson MM, Grimm EA.

Oncol Rep. 2003 Sep-Oct;10(5):1317-20.

PMID:
12883700
19.

Heterozygosity or homozygosity for 2 HLA class II haplotypes predict favorable outcomes for renal cell carcinoma treated with cytokine therapy.

Ellerhorst JA, Hildebrand WH, Cavett JW, Fernandez-Vina MA, Hodges S, Poindexter N, Fischer H, Grimm EA.

J Urol. 2003 Jun;169(6):2084-8.

PMID:
12771724
20.

Negative association of melanoma differentiation-associated gene (mda-7) and inducible nitric oxide synthase (iNOS) in human melanoma: MDA-7 regulates iNOS expression in melanoma cells.

Ekmekcioglu S, Ellerhorst JA, Mumm JB, Zheng M, Broemeling L, Prieto VG, Stewart AL, Mhashilkar AM, Chada S, Grimm EA.

Mol Cancer Ther. 2003 Jan;2(1):9-17.

21.

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Ibrahim NK, Desai N, Legha S, Soon-Shiong P, Theriault RL, Rivera E, Esmaeli B, Ring SE, Bedikian A, Hortobagyi GN, Ellerhorst JA.

Clin Cancer Res. 2002 May;8(5):1038-44.

22.

Phase II trial of 9-nitrocamptothecin (RFS 2000) for patients with metastatic cutaneous or uveal melanoma.

Ellerhorst JA, Bedikian AY, Smith TM, Papadopoulos NE, Plager C, Eton O.

Anticancer Drugs. 2002 Feb;13(2):169-72.

PMID:
11901310
23.

Loss of MDA-7 expression with progression of melanoma.

Ellerhorst JA, Prieto VG, Ekmekcioglu S, Broemeling L, Yekell S, Chada S, Grimm EA.

J Clin Oncol. 2002 Feb 15;20(4):1069-74.

PMID:
11844832
24.

Effects of galectin-3 expression on growth and tumorigenicity of the prostate cancer cell line LNCaP.

Ellerhorst JA, Stephens LC, Nguyen T, Xu XC.

Prostate. 2002 Jan 1;50(1):64-70.

PMID:
11757037
25.

Autoimmunity and hypothyroidism in patients with uveal melanoma.

Ellerhorst JA, Cooksley CD, Grimm EA.

Melanoma Res. 2001 Dec;11(6):633-7.

PMID:
11725210
26.

A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.

Eton O, Buzaid AC, Bedikian AY, Smith TM, Papadopoulos NE, Ellerhorst JA, Hibberts JL, Legha SS, Benjamin RS.

Cancer. 2000 Apr 1;88(7):1703-9.

PMID:
10738230
27.

Melanoma metastatic to the spine: a review of 133 cases.

Gokaslan ZL, Aladag MA, Ellerhorst JA.

Melanoma Res. 2000 Feb;10(1):78-80.

PMID:
10711643
28.

Phase II trial of doxil for patients with metastatic melanoma refractory to frontline therapy.

Ellerhorst JA, Bedikian A, Ring S, Buzaid AC, Eton O, Legha SS.

Oncol Rep. 1999 Sep-Oct;6(5):1097-9.

PMID:
10425308
29.

Phase II trial of alternating weekly chemohormonal therapy for patients with androgen-independent prostate cancer.

Ellerhorst JA, Tu SM, Amato RJ, Finn L, Millikan RE, Pagliaro LC, Jackson A, Logothetis CJ.

Clin Cancer Res. 1997 Dec;3(12 Pt 1):2371-6.

30.

Coincident renal cell carcinoma and nonHodgkin's lymphoma: the M. D. Anderson experience and review of the literature.

Anderson CM, Pusztai L, Palmer JL, Cabanillas F, Ellerhorst JA.

J Urol. 1998 Mar;159(3):714-7. Review.

PMID:
9474132
31.

Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma.

Ellerhorst JA, Sella A, Amato RJ, Tu SM, Millikan RE, Finn LD, Banks M, Logothetis CJ.

Cancer. 1997 Dec 1;80(11):2128-32.

PMID:
9392335
32.

Intraabdominal desmoplastic small cell tumor. Report and discussion of five cases.

Amato RJ, Ellerhorst JA, Ayala AG.

Cancer. 1996 Aug 15;78(4):845-51.

PMID:
8756380
33.

Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial.

Logothetis CJ, Finn LD, Smith T, Kilbourn RG, Ellerhorst JA, Zukiwski AA, Sella A, Tu SM, Amato RJ.

J Clin Oncol. 1995 Sep;13(9):2272-7.

PMID:
7666085
34.

A phase I study of FAP (5-Fluorouracil, α-interferon and cisplatin) combined with methotrexate for the treatment of advanced urothelial malignancies.

Tu SM, Robinson ED, Amato RJ, Ellerhorst JA, Kilbourn RG, Logothetis CJ.

Urol Oncol. 1995 Jul-Aug;1(4):156-60.

PMID:
21224110
35.

Phase II trial of low dose gamma-interferon in metastatic renal cell carcinoma.

Ellerhorst JA, Kilbourn RG, Amato RJ, Zukiwski AA, Jones E, Logothetis CJ.

J Urol. 1994 Sep;152(3):841-5.

PMID:
8051732
36.

2'-deoxy-5-azacytidine increases binding of cisplatin to DNA by a mechanism independent of DNA hypomethylation.

Ellerhorst JA, Frost P, Abbruzzese JL, Newman RA, Chernajovsky Y.

Br J Cancer. 1993 Feb;67(2):209-15. Erratum in: Br J Cancer 1993 Jun;67(6):1444.

37.

Protamine antibody production in diabetic subjects treated with NPH insulin.

Ellerhorst JA, Comstock JP, Nell LJ.

Am J Med Sci. 1990 May;299(5):298-301.

PMID:
2337121
38.

Factors affecting the insulin autoantibody ELISA.

Nell LJ, Hulbert C, Arem R, Marshall RN, Rogers DG, Comstock JP, Ellerhorst JA, Thomas JW.

Autoimmunity. 1989;2(4):299-309.

PMID:
2491613

Supplemental Content

Loading ...
Support Center